Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Innoviva, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Innoviva, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:26 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-335235
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Gross profit | 90,616 | 83,146 | 166,449 | 156,461 |
| Operating expenses: | ||||
| Selling, general and administrative | 34,571 | 26,412 | 67,009 | 53,903 |
| Research and development | 5,190 | 7,983 | 10,431 | 12,379 |
| Total operating expenses | 39,761 | 34,395 | 77,440 | 66,282 |
| Income from operations | 50,855 | 48,751 | 89,009 | 90,179 |
| Changes in fair values of equity method investments, net | (131,834) | 13,082 | 25,816 | (467) |
| Changes in fair values of equity and long-term investments, net | (29,153) | 11,280 | 4,422 | (54,019) |
Item 1. Financial Statements
FAQ
- What is Innoviva, Inc.'s R&D?
- Innoviva, Inc. (INVA) reported R&D of $5.19M in Q2 2026.
- How has Innoviva, Inc.'s R&D changed year-over-year?
- Innoviva, Inc.'s R&D decreased by 35.0% year-over-year, from $7.98M to $5.19M.
- What is the long-term trend for Innoviva, Inc.'s R&D?
- Over 4 years (2021 to 2025), Innoviva, Inc.'s R&D has grown at a 170.0% compound annual growth rate (CAGR), from $576K to $30.6M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Innoviva, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude